UK competition authorities also concerned by proposed Oticon Medical sale
Shortly after the potential sale of Demant’s Oticon Medical division to Cochlear raised eyebrows at the Australian competition authorities, the UK competition council reveals it is also less than happy about the idea.
by marketwire, translated by catherine brett
The UK Competition and Markets Authority (CMA) has expressed concern that the sale of Oticon Medical to Cochlear could have negative effects for hearing implant patients, Bloomberg News reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Potential Demant divestment raises competition concerns
For subscribers
